February 19, 2020
News & Publications
Press Releases
May 16, 2019
H3 Biomedicine to Present Data from Two Ongoing Precision Medicine Clinical Programs at 2019 ASCO Annual Meeting
Phase 1 dose escalation of H3B-6545, a potential first-in-class Selective ERα Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast… Read More »
March 25, 2019
H3 Biomedicine Announces Multiple Presentations at Upcoming AACR Annual Meeting
Presentations highlight company’s expertise seamlessly integrating human biology, data science and modern chemistry to advance a pipeline of investigational breakthrough… Read More »
December 17, 2018
Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3’s RNA Splicing Platform
Read More »
July 10, 2018
Cancer Discovery Features H3 Biomedicine Paper Highlighting Effects of Selective Estrogen Receptor Covalent Antagonists (SERCAs) in ERα Wild-Type and Mutant Breast Cancer Models
Next-generation endocrine therapy exhibits differentiated mechanism of action versus standard-of-care therapies and potently inhibits the ERα pathway H3 Biomedicine’s first… Read More »
April 17, 2018
H3 Biomedicine Reports Discovery of Recurrent RNA Splicing Factor Mutations in Non-Hodgkin’s Lymphoma and Multiple Myeloma
Expands potential addressable patient population for H3 Biomedicine’s lead splicing modulator H3B-8800, currently in Phase 1 study for other hematologic… Read More »In the Media
BioPharm Insight
H3 Biomedicine in active discussions for co-developing its cancer genomics programs – CEO
H3 Biomedicine is in talks with pharma companies to co-develop one or more of its Phase I drugs that are… Read More »
Boston Business Journal
H3 Biomedicine to Begin Trials of First-Ever Gene-Splicing Cancer Drug
Kendall Square-based cancer biotech H3 Biomedicine, created five years ago by Japanese drug firm Eisai, will bring its first drug… Read More »
PharmaVOICE
H3 Biomedicine’s Dr. Lihua Yu Honored in PharmaVOICE 100
In her position as VP, data science and information technology, at H3 Biomedicine, Lihua Yu, Ph.D., is driving the expanded… Read More »
Boston Business Journal
Foundation Medicine, H3 Biomedicine Partner to Develop Cancer Drugs
A partnership announced today between two Cambridge companies, Foundation Medicine (Nasdaq: FMI) and H3 Biomedicine, is further evidence of the… Read More »Scientific Publications
Genes & Development | February 7, 2018
The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action
Somatic mutations in spliceosome proteins lead to dysregulated RNA splicing and are observed in a variety of cancers. These genetic… Read More »
Nature Medicine | February 19, 2018
H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers
Genomic analyses of cancer have identified recurrent point mutations in the RNA splicing factor–encoding genes SF3B1, U2AF1, and SRSF2 that… Read More »
Nature Communications | July 24, 2017
Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer
Muscle-invasive bladder cancer (MIBC) is an aggressive disease with limited therapeutic options. Although immunotherapies are approved for MIBC, the majority… Read More »
Nature Communications | May 25, 2017
Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A–SF3b complex
Pladienolide, herboxidiene and spliceostatin have been identified as splicing modulators that target SF3B1 in the SF3b subcomplex. Here we report… Read More »Media Inquiries
For all media interested in speaking to members of H3 Biomedicine’s executive/scientific team, or receiving further information about the company or pipeline, please forward your request to media@h3biomedicine.com.
